Evidence map›Paper›PMID 29367522›Full record

ArticleJournal of atherosclerosis and thrombosis2018

Low Plasma Levels of Fibroblast Growth Factor-21 in Patients with Peripheral Artery Disease.

Yoshichika Miyazaki, Emi Saita, Yoshimi Kishimoto, Susumu Ibe, Toshiki Seki, Kotaro Miura, Norie Suzuki-Sugihara, Yukinori Ikegami, Reiko Ohmori, Kazuo Kondo and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of atherosclerosis and thrombosis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Adipokines and Inflammation: Focus on Cardiovascular Diseases.International journal of molecular sciences · 2020
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Yoshichika MiyazakiDepartment of Cardiology, National Hospital Organization Tokyo Medical Center.
Emi SaitaEndowed Research Department "Food for Health", Ochanomizu University.
Yoshimi KishimotoEndowed Research Department "Food for Health", Ochanomizu University.
Susumu IbeDepartment of Cardiology, National Hospital Organization Tokyo Medical Center.
Toshiki SekiDepartment of Cardiology, National Hospital Organization Tokyo Medical Center.
Kotaro MiuraDepartment of Cardiology, National Hospital Organization Tokyo Medical Center.
Norie Suzuki-SugiharaGraduate School of Humanities and Sciences, Ochanomizu University.
Yukinori IkegamiDepartment of Cardiology, National Hospital Organization Tokyo Medical Center.
Reiko OhmoriFaculty of Regional Design, Utsunomiya University.
Kazuo KondoEndowed Research Department "Food for Health", Ochanomizu University.
Yukihiko MomiyamaDepartment of Cardiology, National Hospital Organization Tokyo Medical Center.
Ochanomizu University · JPNational Hospital Organization · JPTokyo Medical Center · JPUtsunomiya University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimFibroblast growth factor-21 (FGF-21) is a metabolic regulator with beneficial effects on glucolipid metabolism. Since FGF-21 has lipid-lowering, anti-inflammatory and anti-oxidant properties, it may play a protective role against atherosclerosis. However, blood FGF-21 levels in coronary artery disease (CAD) or peripheral artery disease (PAD) have not been elucidated.

methodsWe measured plasma FGF-21 levels in 417 patients undergoing coronary angiography, who also had ankle-brachial index test for PAD screening.

resultsCAD was found in 224 patients (1-vessel [1-VD], n=92; 2-vessel [2-VD], n=65; 3-vessel disease [3-VD], n=67). No significant difference was found in the FGF-21 levels between 224 patients with CAD and 193 without CAD (median 26.0 vs. 25.9 pg/mL). FGF-21 levels in 4 groups of CAD(-), 1-VD, 2-VD, and 3-VD were 25.9, 37.2, 19.4, and 0.0 pg/mL. FGF-21 tended to be highest in 1-VD and lowest in 3-VD, but the difference did not reach statistical significance. PAD was found in 38 patients. Compared to the 379 patients without PAD, 38 with PAD had CAD more often (87% vs. 50%), especially 3-VD (P＜0.001). FGF-21 levels were lower in patients with PAD than in those without PAD (0.0 vs. 30.7 pg/mL, P＜0.02). In multivariate analysis, the FGF-21 level was an independent factor for PAD, but not for CAD. Odds ratio for PAD was 2.13 (95%CI=1.01-4.49) for a low FGF-21 level (＜15.6 pg/mL).

conclusionNo significant difference was found in the FGF-21 levels between patients with and without CAD. However, FGF-21 levels were low in patients with PAD, and were a factor for PAD independent of atherosclerotic risk factors.

Indexed as

AgedAnkle Brachial IndexAtherosclerosisCoronary AngiographyCoronary Artery DiseaseCross-Sectional StudiesFemaleFibroblast Growth FactorsGene Expression RegulationHumansMaleMiddle AgedPeripheral Arterial DiseaseRisk Factorsfibroblast growth factor 21Fibroblast Growth FactorsCoronary artery diseaseFGF-21Peripheral artery disease

Identifiers

PMID29367522
PMCPMC6143777
OpenAlexW2793038693

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.